Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Diabetic Retinopathy (SUPER-Trial)
NCT02985242Phase 4Terminated
- Sponsor
- Hannover Medical School
- Start
- Jun 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of empagliflozin in diabetic retinopathy (DR) (2 arms), sponsored by Hannover Medical School. Primary endpoint: Microaneurysm formation rate over 12 months at 52 weeks. Started Jun 2017; status: terminated.
02
Drugs
empagliflozin
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT02985242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02985242.